Search alternatives:
large decrease » larger decrease (Expand Search), marked decrease (Expand Search), large increases (Expand Search)
_ decrease » _ decreased (Expand Search), _ decreasing (Expand Search)
a decrease » _ decreased (Expand Search), _ decreases (Expand Search)
may mean » may lead (Expand Search), a mean (Expand Search)
a large » _ large (Expand Search)
Showing 1 - 20 results of 37,424 for search '(((( a large decrease ) OR ( _ ((_ decrease) OR (a decrease)) ))) OR ( may mean decrease ))', query time: 0.74s Refine Results
  1. 1
    Tetrandrine decreases Mtb antigen presentation.

    Tetrandrine decreases Mtb antigen presentation. by Elham Karamooz (2584474)

    Published 2025
    Save to List
    Saved in:
  2. 2
    Table 1_Effect of decreased suspended sediment content on chlorophyll-a in Dongting Lake, China.docx

    Table 1_Effect of decreased suspended sediment content on chlorophyll-a in Dongting Lake, China.docx by Le Zhang (88249)

    Published 2025
    “…<p>Global damming of rivers strongly impacts the transport and characteristic of sediment, resulting in a significant reduction in the suspended sediment content (SSC) flowing into the downstream. …”
    Save to List
    Saved in:
  3. 3
    The PRAME-AS knockout cells showed a decrease in migration, proliferation, stemness, and viability.

    The PRAME-AS knockout cells showed a decrease in migration, proliferation, stemness, and viability. by Zahra Hosseininia (22265113)

    Published 2025
    Save to List
    Saved in:
  4. 4
    nsP4-C483Y or Q192L mutations decrease sensitivity to 4′-FlU.

    nsP4-C483Y or Q192L mutations decrease sensitivity to 4′-FlU. by Peiqi Yin (6533747)

    Published 2025
    Save to List
    Saved in:
  5. 5
    ECoG timescales decrease during spatial attention.

    ECoG timescales decrease during spatial attention. by Isabel Raposo (21615517)

    Published 2025
    “…The individual values for panel A and C are included in <a href="http://www.plosbiology.org/article/info:doi/10.1371/journal.pbio.3003232#pbio.3003232.s005" target="_blank">S2 Data</a>, Experiment 1, 3 and 4 sheets and <a href="http://www.plosbiology.org/article/info:doi/10.1371/journal.pbio.3003232#pbio.3003232.s006" target="_blank">S3 Data</a>, respectively.…”
    Save to List
    Saved in:
  6. 6
    The reduced virulence of Δalta1 mutants is not primarily due to a decrease in growth.

    The reduced virulence of Δalta1 mutants is not primarily due to a decrease in growth. by Shuhuan Zhang (748003)

    Published 2025
    Save to List
    Saved in:
  7. 7
    Expression of lipid biosynthetic genes is decreased with polyamine depletion.

    Expression of lipid biosynthetic genes is decreased with polyamine depletion. by Yazmin E. Cruz-Pulido (20285238)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  8. 8
    Study Flow Diagram.

    Study Flow Diagram. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 9
    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90.

    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 10
    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments).

    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 11
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 12
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 13
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 14
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 15
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 16
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 17
    Long-term anti-nucleocapsid response by baseline patient characteristics.

    Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 18
    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.

    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 19
    Baseline patient characteristics across neutralizing monoclonal antibody trials.

    Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 20
    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies.

    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: